retatrutide clinical trials phase Trials: 28.7% Weight Loss (TRIUMPH-4) New Retatrutide Phase 3 Trial

Tesamorelin has a half-life of approximately 26 minutes after subcutaneous injection, though the growth hormone release it triggers persists for hours

So can taking action with treatments that restore your confidence and align your appearance with your internal transformation

Its also a good option for those who may not tolerate the side effects of the more potent, once-weekly medications

Longer-acting formulations with monthly dosing aim to reduce treatment burden and improve adherence

Aim for at least 0.8 grams of protein per pound of ideal body weight (see IBW calculator here)

Retatrutide, also known by its research name LY-3437943, is an investigational once-weekly injectable drug developed by Eli Lilly